Overview

Fundamentals

Financial Fundamentals

Review latest financial statements, quality scores, TTM ratios, and peer context for this stock.

Company Prime Medicine Inc Healthcare / Biotechnology
Latest report Q1 2026 2026-03-31
Currency USD Local financial statement archive
Filing Open filing 2026-05-07
Revenue $856 000
Gross profit $-1.00M
Operating income $-50.65M
Net income $-49.12M
Free cash flow -
Total debt -
Altman Z -4.57
Piotroski 2.00

Statements

Latest financial statement highlights

Income statement

Revenue $856 000
Cost of revenue $1.86M
Gross profit $-1.00M
Operating expenses $49.65M
EBITDA $-47.27M
Operating income $-50.65M
Income before tax $-49.12M
Net income $-49.12M
EPS -0.280

Cash flow

Operating cash flow -
Capital expenditure -
Free cash flow -
Dividends paid -
Share repurchases -
Net cash change -

Balance sheet

Cash -
Current assets -
Total assets -
Current liabilities -
Total liabilities -
Total debt -
Net debt -
Stockholders equity -

Ratios

Period and TTM ratios

Metric Period TTM
Gross margin - -1 082.70%
Operating margin - -5 121.77%
Net margin - -4 917.55%
Return on equity - -188.82%
Current ratio - 3.80
Quick ratio - 3.80
P/E - -2.56
Price / sales - 145.07
Debt / equity - 1.493
Interest coverage - 0

Peer context

Ratio comparison

Gross margin Best VIR 275.25% PRME -1 082.70% Peer average 35.04%
Return on equity Best PROK 7.40% PRME -188.82% Peer average -59.26%
Current ratio Best TYRA 20.49 PRME 3.80 Peer average 9.54
Debt / equity Best PROK -0.00370 PRME 1.493 Peer average 0.216
P/E Best SEPN -45.15 PRME -2.56 Peer average -9.82